Stay updated on PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial page.

Latest updates to the PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a pilot study involving nivolumab and PAC-1 for metastatic renal cell carcinoma, while adding references to a new version and the drug REN-01.SummaryDifference40%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check84 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check99 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check106 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial page.